Sign up USA
Proactive Investors - Run By Investors For Investors

Catabasis Pharmaceuticals reports positive pre-clinical data for DMD treatment

Dr H Lee Sweeney, who led the research, said: "There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.
Catabasis Pharmaceuticals reports positive pre-clinical data for DMD treatment
The firm reported on pre-clinical data today

Shares in Catabasis Pharmaceuticals Inc (NASDAQ:CATB) advanced as it reported positive pre-clinical data for the treatment of muscle-wasting disease Duchenne muscular dystrophy (DMD).

The data comes from the edasalonexent programme, which showed two inhibitors edasalonexent (CAT-1004) and CAT-1041 are effective in making better the dystrophic process in two animal models.

Dr H Lee Sweeney, who led the research, said: "There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.

"The orally bioavailable NF-kB inhibitors, edasalonexent and CAT-1041, improve the severe dystrophic phenotype found in both mechanically-damaged mdx mice and a GRMD dog and create an environment that can support more successful muscle regeneration."

Catabasis's chief scientific officer Dr Andrew Nichols, added: "We very much appreciate the research performed by Dr Sweeney and his colleagues.

"We agree that these data support edasalonexent as a potential treatment to improve both the quantity and quality of muscle fibers in boys affected by DMD and look forward to the Phase 2 clinical trial results with edasalonexent in the first half of Q1 2017."

Another DMD firm -  Summit Therapeutics (LON:SUMM) is in a phase II trial with its potentially breakthrough treatment for the disease.

In October, it inked a licensing deal with US biotech Sarepta Therapeutics (NASDAQ:SRPT) worth up to US$522mln.

Shares added 2.49% to US$3.70.

Giles_55af4ddca6481.jpg


Register here to be notified of future CATB Company articles
View full CATB profile

Catabasis Pharma Timeline

Related Articles

Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
eye-766166_1280_583251a48f148.jpg
November 20 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use